NDMA investigation leads to cases discovered in diabetes treatment

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Oakozhan)
(Image: Getty/Oakozhan)

Related tags: Metformin, Diabetes, Singapore, Sartan, Ranitidine, Nitrosamine

After NDMA contamination is found by Singaporean authorities, both the FDA and EMA state they are working on the testing of metformin treatments.

Both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have released regular updates into their investigations into the causes of medicine contamination with nitrosamines.

With a number of ‘sartan’ medications affected by recalls, the FDA expedited the approval of a valsartan generic earlier this year​. While various companies issued voluntary recalls due to the finding of similar contamination in ranitidine medicines​.

The global investigation has now expanded to include metformin treatment, after the Singaporean government revealed that it had recalled three out of 46 metformin medicines​ on the market. Again, this action had been taken due to the presence of N-nitrosodimethylamine (NDMA).

In the US and the European Union (EU), there are currently no recalls of the oral diabetes treatment and the EMA stated that “there are no data indicating that EU metformin medicines are affected” ​– though both agencies noted that they were engaging in the expedited testing of metformin medicines.

The FDA emphasized the low risk posed by ingesting NDMA, or such substances, at levels that the agency deems acceptable, adding that it is possible to take a drug with low levels of NDMA every day for 70 years without an increased risk of cancer.

Despite moving to reassure patients taking the treatment, the agency also warned that further medicines could be discovered to be contaminated with nitrosamines, as the investigation continues.

A statement from Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, read: “As our investigations and testing continues, along with the investigations done by other drug regulatory agencies, we may find low levels of nitrosamines in additional drugs.”

Related news

Show more

Related products

How to resolve sticking issues in tablet production

How to resolve sticking issues in tablet production

I Holland Limited - Tabletting Science | 24-Jun-2019 | Case Study

Tablet sticking is one of the most common problems in tablet manufacture. Find out how I Holland used the TSAR scientific predictive model and expert tablet...

How to measure powder and granule flow properties

How to measure powder and granule flow properties

Stable Micro Systems | 01-Apr-2019 | Technical / White Paper

Being able to predict, optimise and control powder flow is of prime importance to manufacturers in ensuring high quality standards. Download this free...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more

Webinars